NDAINTRAVENOUSSOLUTION
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
12.1 Mechanism of Action Daptomycin is an antibacterial drug [see ] . 12.2 Pharmacodynamics Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for…
Pharmacologic Class:
Lipopeptide Antibacterial
Indications (19)
pneumonialeft-sided infective endocarditis due to Scomplicated skinskin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates)Streptococcus pyogenesStreptococcus agalactiaeStreptococcus dysgalactiae subspStaphylococcus aureus bloodstream infections (bacteremia)including adult patients with right-sided infective endocarditiscaused by methicillin-susceptiblemethicillin-resistant isolatesdevelopment of drug-resistant bacteriamaintain the effectiveness of Daptomycin in Sodium Chloride Injectionother antibacterial drugsDaptomycin in Sodium Chloride Injection should be used to treatprevent infectionsstrongly suspected to be caused by bacteriaDaptomycin in Sodium Chloride Injection should be used only to treatstrongly suspected to be caused by susceptible bacteria
Loss of Exclusivity
LOE Date
Mar 11, 2041
182 months away
Patent Expiry
Mar 11, 2041
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 11173189 | Mar 11, 2041 | Product | U-3294 |
Company
B
Baxter
Costa Rica - Cartago